top of page
Welcome to

American Heart Technologies

The home of innovative healthtech solutions.

Founded by

Dr. Morteza Naghavi

Healthcare In Dire Need Of Innovation

Get in touch if you want to help us with our next project



Great ideas require the guidance and financial support of insightful, visionary investors to come to fruition. We welcome healthcare investors who would like to invest in innovative healthcare technologies that have the potential to improve peoples’ lives while achieving financial success. Please send us a short email and we will get back to you promptly.


We are inviting entrepreneurs with a proven track record in med tech space as well as MBA graduates with a strong drive to enter into the medical technology world, to contact us and learn about mutual opportunities.


Welcome to
the future of Healthcare

American Heart Technologies and it’s investment arm, MEDITEX, were founded by Dr. Morteza Naghavi as a vehicle to transform innovative ideas into novel solutions for patient care and preventive care. In collaboration with outstanding minds including MDs, PhDs., and business consultants, our team has pioneered a number of innovative solutions. At the core of our team, there is a strong and passionate commitment to advancing the status quo from sick care and symptomatic medicine to healthcare and preventive personalized medicine.

By incorporating machine learning and robotics into medical innovations, we aim to bring diagnostic and therapeutic technologies from hospitals and specialized clinics to primary care offices and patients’ home. We welcome your interest to collaborate with us or invest in our projects.

The future of health is smart

How can an intelligent health ecosystem create a smarter health experience?

Three essential shifts to build and elevate a smarter health experience.


Meet Dr. Morteza Naghavi

Dr. Naghavi is a physician scientist, entrepreneur and venture capitalist with interests in preventive healthcare and medical technologies. He graduated as a M.D. from Tehran University and was trained as a cardiovascular physician scientist at the University of Texas Health Science Center and Texas Heart Institute under distinguished cardiologists late Dr. Ward Casscells and late Dr. James T. Willerson. He was also mentored by Dr. Valentin Fuster the Physician-in-Chief of Mount Sinai Hospital in New York and the past president of American Heart Association. Dr. Naghavi is the founder of SHAPE (Society for Heart Attack Prevention and Eradication) and is recognized as an innovative leader in the fields of Vulnerable Plaque and Vulnerable Patient for the early detection and treatment of asymptomatic atherosclerotic cardiovascular disease. Dr. Naghavi has numerous inventions and founded several medical companies. He is currently the President and CEO of American Heart Technologies.

"The best way to predict the future is to create it" and that is what we are working hard at. We predict the future of healthcare will be preventive care and shifted away from physicians' offices to people's home powered by AI, smart robots, and low cost medical devices.

Feel free to get in touch if you wish to help create the future of healthcare.


David Yankelevitz MD2.png


Dr. David Yankelevitz is a Professor of Radiology and the Director of the Lung Biopsy Service at the Icahn School of Medicine. Dr. Yankelevitz’s main academic interest is in the evaluation of treatments for early-diagnosed lung cancer; and he has been the Co-Principal Investigator of the Initiative for Early Lung Cancer Research on Treatment (IELCART) . In addition to the IELCART research, Dr. Yankelevitz has, for the past 20 years, been a Co-Principal Investigator of the International Early Lung Cancer Action Program (I-ELCAP) and has co-authored over 300 peer-reviewed articles and book chapters, and he has trained 40 Research Fellows in thoracic imaging. Prior to joining the faculty at Mount Sinai in 2010, he was a Professor of Radiology at Weill Cornell Medical College in New York City. Dr. Yankelevitz is a collaborator of Dr. Naghavi and contributed to Dr. Naghavi’s NIH grant application for early detection of CVD and lung cancer using machine learning chest CT scans.



Dr. Reeves a professor of engineering and computer science at Cornell University. He has also held a faculty position in the Department of Radiology at the Weill Medical College of Cornell University. Dr. Reeves’ research is focused on computer methods for analyzing digital images especially with regards to accurate image measurements and with a primary focus on biomedical applications. In collaboration with radiologists at the Weill Medical College of Cornell University and Mount Sinai hospital he working on automatic detection and diagnosis of lung cancer from Computer Tomography (CT) scans and the computer aided diagnosis of diseases within the chest. In collaboration with Dr. Naghavi and Dr. Budoff he has been researching early detection of heart disease using chest CT scans for automatic detection of coronary artery calcium (CSC) score and other complementary findings.


M.D., Ph.D.

Dr. Henschke is a pioneer and leading expert in diagnostic radiology with more than 25 years of clinical and research experience with low-dose CT screening; and she has led the implementation of numerous city, state, national, and international lung screening programs. Since the start, in 1992, of the Early Lung Cancer Action Project (ELCAP) Dr. Henschke has worked on advancing the CT screening research of early lung disease, with a particular focus on lung cancer. In addition, the success of the I-ELCAP program led to another multi-national study, The Initiative for Early Lung Cancer Research on Treatment (IELCART), implemented in 2016 to assess the efficacy of various early lung cancer treatments. Dr. Henschke has authored over 400 peer-reviewed publications, two books, many scientific presentations, and has trained over 80 physician researchers. Dr. Henschke is a collaborator of Dr. Naghavi and contributed to Dr. Naghavi’s NIH grant application for early detection of CVD and lung cancer using machine learning chest CT scans.


Javier Zulueta,


Dr. Zulueta is a world-renowned professor of pulmonology at Mount Sinai Medical Center and Medical Center. He is a Fellow of the American College of Chest Physicians and Member of the American Thoracic Society, American Respiratory Society, European Respiratory Society and Spanish Association of Pulmonary Medicine and Thoracic Surgery. Dr. Zulueta is a member of HeartLung medical leadership team..

Dong Li MD.PhD.jpg

Dong Li, M.D., Ph.D. 

Assistant Professor of Medicine. Emory University School of Medicine. Emory University Learning Outcomes Assessment Committee (LOAC). Core Faculty Members, Socio-ecological and Behavioral Science for Equity. Georgia Center for Diabetes Translation Research.

Dr. Li is a cardiovascular epidemiologist at Emory University School of Medicine, with joint appointments at Emory Global Diabetes Research Center. Dr. Li is a pioneer in artificial intelligence (AI) applications in healthcare. His primary research interest is AI in diagnostic medical imaging. He has authored over 90 papers, 125 conference abstracts, and co-edited four textbooks. Dr. Li has lectured locally, nationally, and internationally on various topics related to AI applications in healthcare.



Dr. Kleis is a Professor (Emeritus) of Mechanical Engineering at the University of Houston. Dr. Kleis, who holds a Ph.D. from Michigan State University, has worked with NASA for nearly 20 years to enhance the functionality of its bioreactors. He was principle investigator on two space shuttle flight experiments and received one of NASA’s highest honors, the Public Service Medal. He has expertise in fluid mechanics and heat and mass transport with emphasis on experimental measurements and applied computational fluid dynamics. Dr. Kleis and his then PhD students; Dr. Wasy Akhtar, collaborated with Dr. Naghavi on the development of VENDYS endothelial function monitoring technology based on measuring temperature changes at the fingertip during a 5-minute arm-cuff occlusion and release. This technology is now an FDA approved medical device available throughout United States and Europe.

bottom of page